Efficacy and safety in patients with psoriasis treated continuously with adalimumab for approximately 3 years

被引：0
|
作者：
Gordon, Kenneth [1 ]
Sasso, Eric [2 ]
Gu, Yihua [2 ]
Poulin, Yves [3 ]
机构：
[1] NorthShore Univ HealthSystem, Evanston, IL USA
[2] Abbott, Abbott Pk, IL USA
[3] Ctr Dermatol Quebec Metropolitain, Quebec City, PQ, Canada
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2010年 / 62卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：AB140 / AB140
页数：1
相关论文
共 50 条
  • [31] Efficacy and safety of adalimumab in psoriatic patients previously treated with etanercept in a real-world setting
    Fonseca, Eduardo
    Iglesias, Raquel
    Paradela, Sabela
    Fernandez-Torres, Rosa M.
    Elberdin, Laida
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2015, 26 (03) : 217 - 222
  • [32] Efficacy and Safety of Roxadustat in Patients with Anemia of Non-Dialysis-Dependent CKD (NDD-CKD) Treated Continuously for ≥2 Years
    Pecoits-Filho, Roberto
    Dahl, Neera K.
    Tham, Stefan
    Orias, Marcelo
    Hao, Chuan-Ming
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 180 - 180
  • [33] Efficacy and safety of Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis: Results from the Phase 3 IMMvent trial
    Reich, K.
    Gooderham, M.
    Thaci, D.
    Crowley, J. J.
    Ryan, C.
    Kruger, J. G.
    Tsai, T.
    Flack, M.
    Gu, Y.
    Williams, D. A.
    Thompson, E. H.
    Paul, C.
    EXPERIMENTAL DERMATOLOGY, 2019, 28 (03) : E24 - E25
  • [34] Adalimumab long-term safety/efficacy results for pediatric patients with chronic plaque psoriasis from a phase 3, randomized study
    Papp, Kim
    Marcoux, Danielle
    Landells, Ian
    Weibel, Lisa
    Ghislain, Pierre-Dominique
    Unnebrink, Kristina
    Williams, David
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB209 - AB209
  • [35] Efficacy and Safety Similarity of Biosimilar Adalimumab-aqvh to Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Phase III Study
    Finck, Barbara
    Tang, Helen
    Jensen, Kathy
    Civoli, Francesca
    Tatarewicz, Suzanna
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 3620 - 3621
  • [36] Safety and efficacy of adalimumab in pediatric patients with Crohn disease
    Wyneski, Matthew J.
    Green, Alex
    Kay, Marsha
    Wyllie, Robert
    Mahajan, Lori
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2008, 47 (01): : 19 - 25
  • [37] Drug concentration and antidrug antibodies in patients with psoriasis treated with adalimumab or etanercept
    Gyldenlove, M.
    Zachariae, C.
    Jensen, P.
    Griehsel, H.
    Stahle, M.
    Skov, L.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (12) : E518 - E519
  • [38] Adalimumab treats psoriasis in patients previously treated with etanercept: A case series
    Yamauchi, Paul S.
    Mau, Nicole
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2009, 61 (01) : 158 - 160
  • [39] Weight and demographic characteristics of psoriasis patients treated with adalimumab, etanercept, or ustekinumab
    Meyer, Roxanne
    Yeaw, Jason
    Zhang, Mingliang
    Hines, Dionne
    Wade, Ron
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB257 - AB257
  • [40] Long-term remission, efficacy and safety in patients with rheumatoid arthritis treated with adalimumab (Humira®) plus methotrexate for more than 5 years
    Breedveld, FC
    Rau, R
    Van Riel, P
    van de Putte, L
    Schattenkirchner, M
    Kupper, H
    Segurado, O
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 268 - 268
12345